Scarica l'app Stockscreener
2.28
7.04%
0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.13
Aprire:
$2.15
Volume 24 ore:
11,590
Relative Volume:
0.60
Capitalizzazione di mercato:
$3.44M
Reddito:
-
Utile/perdita netta:
$-36.46M
Rapporto P/E:
-14.25
EPS:
-0.16
Flusso di cassa netto:
$-30.20M
1 W Prestazione:
-2.46%
1M Prestazione:
+5.56%
6M Prestazione:
-78.69%
1 anno Prestazione:
-79.54%
Intervallo 1D:
$2.15
$2.34
Intervallo di 1 settimana:
$2.07
$2.411
Portata 52W:
$1.95
$32.85
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Nome
Alaunos Therapeutics Inc
Settore
Industria
Telefono
(346) 355-4099
Indirizzo
2617 BISSONNET ST, HOUSTON
Confronta TCRT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| TCRT | 2.27 | 3.44M | 0 | -36.46M | -30.20M | -0.16 |
| VRTX | 450.44 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.45 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.35 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Borsa (TCRT) Ultime notizie
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
An Analysis of Atricure Inc (ATRC)’s Potential Price Growth - Knox Daily
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Applied Therapeutics jumps as US FDA cancels panel meeting for genetic disorder drug - XM
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Daily Market Movement: Atricure Inc (ATRC) Sees a -3.23 Decrease, Closing at 27.30 - The Dwinnex
Aptevo Therapeutics announces $3.0M offering priced at-the-market - TipRanks
Check out these key findings about Atricure Inc (ATRC) - SETE News
Atmos Energy Co. (NYSE:ATO) Shares Sold by Prudential PLC - MarketBeat
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Ziopharm: Q2 Earnings Snapshot - San Antonio Express-News
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 4.2% - Defense World
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
TCRT stock touches 52-week low at $3.57 amid market challenges - Investing.com Nigeria
Alaunos Therapeutics announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Intracranial Therapeutic Industry Startegy Analysis} Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics ... - Economica
Alaunos (TCRT) Dips More Than Broader Markets: What You Should Know - Yahoo New Zealand News
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings ... - Yahoo Lifestyle UK
Alaunos Therapeutics appoints new accounting firmInvesting.com ZA - Investing.com South Africa
Alaunos Therapeutics appoints new accounting firm By Investing.com - Investing.com
Ziopharm Oncology to Participate in Upcoming Conferences - Quantisnow
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25 ... - Quantisnow
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations - Quantisnow
New Strong Buy Stocks for November 18th - Yahoo Movies Canada
Commerce Bank Decreases Stock Position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) - Defense World
The past five years for Alaunos Therapeutics (NASDAQ:TCRT) investors has not been profitable - Yahoo News Australia
Quarterly Metrics: Quick and Current Ratios for Alaunos Therapeutics Inc (TCRT) – DWinneX - The Dwinnex
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
Alaunos Therapeutics Reports First Quarter 2023 Financial Results - br.ADVFN.com
AltruBio secures $225m for immune checkpoint programme development - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 3.6% - Defense World
Alaunos Therapeutics (NASDAQ:TCRT) investors are sitting on a loss of 78% if they invested three years ago - Yahoo Lifestyle UK
Alaunos Therapeutics Inc Azioni (TCRT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):